Johnson & Johnson reorganizes its PR team

Share this article:
Johnson & Johnson (J&J) has announced a restructuring of its public affairs and corporate communications team.

The changes, first reported by MM&M sibling publication PRWeek, follow the retirement of Nancy Walker, J&J's former VP of global pharmaceutical communications, the promotion of Anthony Carter from VP corporate communications to chief diversity officer, and the March 2009 retirement of Dave Swearingen. The new team will absorb Carter and Walker's duties, as well as Swearingen's upon his retirement, according to J&J.

In an internal notice distributed on October 3, the company announced that senior communication leaders would be linked directly with stakeholder groups. Under the new organization, six VPs will report to Ray Jordan, VP of public affairs and corporate communication: Sarah Colamarino, VP, corporate communication; Jeff Leebaw, VP, corporate communication; Pat Molino, VP, public affairs and corporate citizenship; Susan Odenthal, VP, corporate communication; Craig Rothenberg, VP, corporate communication; Swearingen will retire—as mentioned—in March 2009, but will be tasked with helping to ensure an effective transition of his responsibilities.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?